Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) Gross Profit: 2020-2025

Historic Gross Profit for Foghorn Therapeutics (FHTX) over the last 6 years, with Sep 2025 value amounting to $8.2 million.

  • Foghorn Therapeutics' Gross Profit rose 4.42% to $8.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.5 million, marking a year-over-year decrease of 3.91%. This contributed to the annual value of $22.6 million for FY2024, which is 33.83% down from last year.
  • According to the latest figures from Q3 2025, Foghorn Therapeutics' Gross Profit is $8.2 million, which was up 7.89% from $7.6 million recorded in Q2 2025.
  • Foghorn Therapeutics' Gross Profit's 5-year high stood at $17.5 million during Q3 2023, with a 5-year trough of $41,000 in Q3 2021.
  • Its 3-year average for Gross Profit is $7.1 million, with a median of $6.0 million in 2025.
  • In the last 5 years, Foghorn Therapeutics' Gross Profit slumped by 77.09% in 2021 and then soared by 16,080.49% in 2022.
  • Over the past 5 years, Foghorn Therapeutics' Gross Profit (Quarterly) stood at $713,000 in 2021, then skyrocketed by 486.82% to $4.2 million in 2022, then skyrocketed by 37.88% to $5.8 million in 2023, then tumbled by 50.49% to $2.9 million in 2024, then increased by 4.42% to $8.2 million in 2025.
  • Its last three reported values are $8.2 million in Q3 2025, $7.6 million for Q2 2025, and $6.0 million during Q1 2025.